NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NICHD E-552-2013-0-PCT-02 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE PCT PCT PCT/US2014/067415 Expired
NIAID E-170-2013-1-PCT-01 CHIMERIC ANTIGEN RECEPTORS TO CONTROL HIV INFECTION PCT PCT COMB PCT/US2014/067459 Expired
NINDS E-017-2015-0-US-01 Compounds Targeting Hypoxia-inducible Factor 2 Alpha US 62/084,455 Abandoned
NIDDK E-194-2012-0-US-03 Eukaryotic Transposase Mutants And Transposon End Compositions For Modifying Nucleic Acids And Methods For Production And Use In The Generation Of Sequencing Libraries US National Stage 14/403,506 Abandoned
NIA E-139-2012-2-US-06 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES US National Stage 14/403,516 Abandoned
NICHD E-008-2015-0-US-01 Joint Probability Distrbution Determinations for Material Assessments US 62/083,834 Abandoned
NHLBI E-124-2014-1-US-01 Devices and Methods For Closure Of Transvascular Or Transcameral Access Ports US 62/083,192 Abandoned
NIA E-139-2012-2-JP-05 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES JP National Stage 2015-514191 Issued
NHLBI E-122-2006-0-US-04 COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF NEOPLASTIC DISEASE IN A MAMMALIAN SUBJECT US CON 14/549,296 9856453 Issued PDF
NIDDK E-011-2014-0-PCT-02 Heterocyclic Compounds and Methods of Use Thereof PCT PCT PCT/US2014/066680 Expired
NIDDK E-742-2013-0-PCT-02 A3 Adenosine Receptor Agonists PCT PCT PCT/US2014/066609 Expired
NIDDK E-011-2014-0-EP-07 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer EP National Stage 14809235.6 Abandoned
NIDDK E-011-2014-0-KR-10 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer KR National Stage 10-2016-7014314 Abandoned
NIDDK E-011-2014-0-CA-05 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer CA National Stage 2931804 Abandoned
NIDDK E-011-2014-0-AU-04 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer AU National Stage 2014354957 Abandoned
NCI E-025-2009-0-CA-05 Ratio Based Biomarkers And Methods of Use Thereof CA National Stage 2749601 Issued
NCI E-105-2012-0-NL-25 Murine Anti-NY-ESO-1 T Cell Receptors NL EP 13726389.3 Issued
NCI E-105-2012-0-PT-26 Murine Anti-NY-ESO-1 T Cell Receptors PT EP 13726389.3 Issued
NCI E-105-2012-0-CH-18 Murine Anti-NY-ESO-1 T Cell Receptors CH EP 13726389.3 Issued
NCI E-105-2012-0-ES-20 Murine Anti-NY-ESO-1 T Cell Receptors ES EP 13726389.3 Issued
NCI E-105-2012-0-GB-22 Murine Anti-NY-ESO-1 T Cell Receptors GB EP 13726389.3 Issued
NCI E-105-2012-0-BE-17 Murine Anti-NY-ESO-1 T Cell Receptors BE EP 13726389.3 Issued
NCI E-105-2012-0-AT-16 Murine Anti-NY-ESO-1 T Cell Receptors AT EP 13726389.3 Issued
NCI E-105-2012-0-DE-19 Murine Anti-NY-ESO-1 T Cell Receptors DE EP 13726389.3 Issued
NCI E-105-2012-0-FR-21 Murine Anti-NY-ESO-1 T Cell Receptors FR EP 13726389.3 Issued
NCI E-105-2012-0-IE-23 Murine Anti-NY-ESO-1 T Cell Receptors IE EP 13726389.3 Issued
NCI E-105-2012-0-IT-24 Murine Anti-NY-ESO-1 T Cell Receptors IT EP 13726389.3 Issued
NCI E-105-2012-0-US-09 Murine Anti-NY-ESO-1 T Cell Receptors US National Stage 14/401,893 9487573 Issued PDF
NCI E-263-2011-0-HK-07 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes HK EP 14111650.2 Abandoned
NCI E-105-2012-0-JP-08 Murine Anti-NY-ESO-1 T Cell Receptors JP National Stage 2015-514144 Issued
NIAID E-275-2008-2-US-04 Preventing or Treating Viral Infection Using an Inhibitor of the LSD1 Protein, A MAO Inhibitor or an Inhibitor of LSD1 and a MAO Inhibitor US DIV 14/543,321 9499821 Abandoned PDF
NCI E-105-2012-0-IL-07 Murine Anti-NY-ESO-1 T Cell Receptors IL National Stage 235720 Issued
NIAMS E-762-2013-1-CA-03 ENGINEERING NEURAL STEM CELLS USING HOMOLOGOUS RECOMBINATION CA National Stage 2930590 Issued
NIAMS E-762-2013-1-PCT-01 ENGINEERING NEURAL STEM CELLS USING HOMOLOGOUS RECOMBINATION PCT PCT COMB PCT/US2014/065769 Expired
NCATS E-751-2013-0-PCT-02 Method of Blocking Transmission of Malarial Parasite PCT PCT PCT/US2014/065671 Expired
NCI E-226-2014-0-US-01 Anti-Human Thyroglobulin T Cell Receptors US 62/079,713 Abandoned
NHLBI E-036-2015-0-US-01 NK Cells with an Increased Antibody-Dependent Cellular Toxicity (ADCC) Against Tumors US 62/079,975 Abandoned
NIDDK E-034-2015-0-US-01 Device and System for Manipulating Small Model Organisms US 62/080,181 Abandoned
NIAID E-278-2016-0-US-01 Antibodies That Neutralize Ebola Virus And Uses Thereof US 62/080,094 Abandoned
NCI E-256-2008-0-US-06 Survival Predictor for Diffuse Large B Cell Lymphoma US CON 14/540,302 9970059 Issued PDF
NHLBI E-516-2013-0-PCT-02 DETECTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK AND MYOCARDIAL INFARCTION RISK PCT PCT PCT/US2014/065527 Expired
NHLBI E-515-2013-0-PCT-02 DETECTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK AND HEART FAILURE RISK PCT PCT PCT/US2014/065524 Expired
NCI E-273-2011-0-US-03 Cross-Reactive Antibodies Against Dengue Virus And Uses Thereof US National Stage 14/400,642 9556254 Abandoned PDF
NICHD E-039-2016-0-US-01 METHOD FOR TREATMENT OF HORMONAL DISORDERS OF GROWTH USING ANTAGONlSTS AND AGONISTS OF THE ORPHAN G-PROTEIN COUPLED RECEPTOR {GPCR), GPR101 US 62/078,517 Abandoned
NCI E-040-2012-0-KR-16 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen KR National Stage 10-2014-7031520 Issued
NIAID E-152-2015-0-US-01 Probiotic Therapeutic Applications US 62/077,534 Abandoned
CC E-149-2014-0-US-01 Topical Sodium Nitrate Formulation US 62/077,622 Abandoned
NIMH E-043-1997-2-CN-22 Methods for Expression and Purification of Immunotoxins CN DIV 2014106436989 Abandoned
NIAID E-214-2015-0-AU-05 Conformationally Specific Viral Immunogens AU National Stage 2013259548 Abandoned
NCI E-007-2014-0-GB-07 ALK ANTIBODIES, CONJUGATES, AND CHIMERIC ANTIGEN RECEPTORS, AND THEIR USE GB EP 14805427.3 Abandoned